Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9183-9198

  Raz, Shachar ^a   Stark, Michal ^a   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antifolate resistance; FPGS; Intragenic regulatory element; Leukemia; Smad transcription factors

Indexed keywords

ADENOSINE TRIPHOSPHATE; COMPLEMENTARY DNA; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; SMAD4 PROTEIN; TRANSCRIPTION FACTOR ETS 1; DNA HELICASE; ETS1 PROTEIN, HUMAN; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PEPTIDE SYNTHASE; PROTEIN BINDING; SMAD4 PROTEIN, HUMAN; SMARCA4 PROTEIN, HUMAN; TETRAHYDROFOLATE SYNTHASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; EXON; FPGS GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; GENE SILENCING; HETEROZYGOSITY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOSYNTHESIS; DNA METHYLATION; DRUG RESISTANCE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA HELICASES; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLIC ACID ANTAGONISTS; GENE SILENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-ETS-1; SEQUENCE ANALYSIS, DNA; SMAD4 PROTEIN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84910029508     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2399     Document Type: Article

References (44)

1. Assaraf YG. Molecular basis of antifolate resistance. Cancer metastasis reviews. 2007; 26(1):153-181.
2. Gonen N and Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012; 15(4):183-210.
3. Zeng H, Chen ZS, Belinsky MG, Rea PA and Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer research. 2001; 61(19):7225-7232.
4. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat. 2006; 9(4-5):227-246.
5. Stark M, Wichman C, M. Stark et al, Avivi I and Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood. 2009; 113(18):4362-4369.
6. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A and Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood. 1990; 76(1):44-49.
7. Goker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI and Bertino JR. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia. 1993; 7(7):1000-1004.
8. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH and Evans WE. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest. 1996; 97(1):73-80.
9. Bienemann K, Staege MS, Howe SJ, Sena-Esteves M, Hanenberg H and Kramm CM. Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells. Cancer gene therapy. 2013; 20(9):514-520.
10. Lin JT, Tong WP, Trippett TM, Niedzwiecki D, Tao Y, Tan C, Steinherz P, Schweitzer BI and Bertino JR. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res. 1991; 15(12):1191-1196.
11. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G and Assaraf YG. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003; 103(5):587-599.
12. Leclerc GJ, York TA, Hsieh-Kinser T and Barredo JC. Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line. Leuk Res. 2007; 31(3):293-299.
13. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014; 106(2):djt369.
14. Itoh S, Itoh F, Goumans MJ and Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem. 2000; 267(24):6954-6967.
15. Morikawa M, Koinuma D, Miyazono K and Heldin CH. Genome-wide mechanisms of Smad binding. Oncogene. 2013; 32(13):1609-1615.
16. Xi Q, He W, Zhang XH, Le HV and Massague J. Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program. The Journal of biological chemistry. 2008; 283(2):1146-1155.
17. Moustakas A, Pardali K, Gaal A and Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunology letters. 2002; 82(1-2):85-91.
18. Frontelo P, Leader JE, Yoo N, Potocki AC, Crawford M, Kulik M and Lechleider RJ. Suv39h histone methyltransferases interact with Smads and cooperate in BMP-induced repression. Oncogene. 2004; 23(30):5242-5251.
19. Kim SJ and Letterio J. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia. 2003; 17(9):1731-1737.
20. Sun X, Cross JA, Bognar AL, Baker EN and Smith CA. Folate-binding triggers the activation of folylpolyglutamate synthetase. Journal of molecular biology. 2001; 310(5):1067-1078.
21. Freemantle SJ and Moran RG. Transcription of the human folylpoly-gamma-glutamate synthetase gene. The Journal of biological chemistry. 1997; 272(40):25373-25379.
22. Leclerc GJ, Mou C, Leclerc GM, Mian AM and Barredo JC. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia. 2010; 24(3):552-562.
23. Kulis M, Queiros AC, Beekman R and Martin-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochimica et biophysica acta. 2013; 1829(11):1161-1174.
24. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine VM, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010; 466(7303):253-257.
25. Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA and Barton MC. A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. Molecular and cellular biology. 2005; 25(3):1200-1212.
26. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M and Thiagalingam S. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer research. 2010; 70(3):968-978.
27. Subtil-Rodriguez A and Reyes JC. BRG1 helps RNA polymerase II to overcome a nucleosomal barrier during elongation, in vivo. EMBO Rep. 2010; 11(10):751-757.
28. Hodges C, Bintu L, Lubkowska L, Kashlev M and Bustamante C. Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II. Science. 2009; 325(5940):626-628.
29. Zhou P, Luo Y, Liu X, Fan L and Lu Y. Down-regulation and CpG island hypermethylation of CRYAA in age-related nuclear cataract. Faseb J. 2012; 26(12):4897-4902.
30. Leclerc GJ, Leclerc GM, Kinser TT and Barredo JC. Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells. BMC cancer. 2006; 6:132.
31. Goffin V, Demonte D, Vanhulle C, de Walque S, de Launoit Y, Burny A, Collette Y and Van Lint C. Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. Nucleic acids research. 2005; 33(13):4285-4310.
32. Seuter S, Sorg BL and Steinhilber D. The coding sequence mediates induction of 5-lipoxygenase expression by Smads3/4. Biochemical and biophysical research communications. 2006; 348(4):1403-1410.
33. Kieffer-Kwon KR, Tang Z, Mathe E, Qian J, Sung MH, Li G, Resch W, Baek S, Pruett N, Grontved L, Vian L, Nelson S, Zare H, Hakim O, Reyon D, Yamane A, et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell. 2013; 155(7):1507-1520.
34. Koinuma D, Tsutsumi S, Kamimura N, Imamura T, Aburatani H and Miyazono K. Promoter-wide analysis of Smad4 binding sites in human epithelial cells. Cancer science. 2009; 100(11):2133-2142.
35. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS and Arteaga CL. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013; 123(3):1348-1358.
36. Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C and Giannelli G. Differential Inhibition of the TGF-beta Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-beta Receptor Type II. PloS one. 2013; 8(6):e67109.
37. Leclerc GJ and Barredo JC. Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(4):942-951.
38. Makia NL, Surapureddi S, Monostory K, Prough RA and Goldstein JA. Regulation of Human CYP2C9 Expression by Electrophilic Stress Involves AP-1 Activation and DNA Looping. Mol Pharmacol. 2014.
39. Narlikar GJ, Fan HY and Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell. 2002; 108(4):475-487.
40. Harikrishnan KN, Chow MZ, Baker EK, Pal S, Bassal S, Brasacchio D, Wang L, Craig JM, Jones PL, Sif S and El-Osta A. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet. 2005; 37(3):254-264.
41. Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM and Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer research. 2007; 67(18):8772-8782.
42. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46(3):225-233.
43. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G and Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J. 2002; 367(Pt 3):741-750.
44. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-1612.